Allergan: BELKYRA Receives Marketing Authorisation In Sweden - Quick Facts

(RTTNews) - Allergan plc (AGN) announced that BELKYRA (deoxycholic acid) has been granted approval by the Swedish Medical Products Agency. BELKYRA is a prescription medicine for the treatment of moderate-to-severe convexity or fullness associated with submental fat (often called double chin) in adults when the presence of submental fat has a psychological impact for the patient.

Bill Meury, Chief Commercial Officer, Allergan said: "We believe BELKYRA will be a breakthrough treatment in Europe, as it has been in the United States and Canada, and it complements our established medical aesthetics portfolio. We look forward to introducing BELKYRA to other countries around Europe over the coming months, as we secure the additional national approvals."

BELKYRA is already licensed in Canada, Australia, Iceland, Hungary, Austria, Lithuania, Estonia, Latvia, Romania, Bulgaria and Norway, as well as in the U.S. as KYBELLA.